Infliximab Treatment and Quality of Life in Rheumatic Diseases
Author Information
Author(s): Han Chenglong, Smolen Josef S, Kavanaugh Arthur, van der Heijde Désirée, Braun Jürgen, Westhovens René, Zhao Ning, Rahman Mahboob U, Baker Daniel, Bala Mohan
Primary Institution: Centocor Research and Development, Inc.
Hypothesis
How does infliximab treatment affect the quality of life in patients with inflammatory rheumatic diseases?
Conclusion
Infliximab treatment significantly improves health-related quality of life in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Supporting Evidence
- Patients treated with infliximab showed significant improvement in physical component summary scores compared to placebo.
- The improvement in health-related quality of life was maintained over time in patients receiving infliximab.
- Patients with RA and PsA had greater improvements in mental component summary scores than those receiving placebo.
Takeaway
This study shows that a medicine called infliximab helps people with certain types of arthritis feel better and live better lives.
Methodology
The study analyzed SF-36 data from four clinical trials involving patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Potential Biases
Potential biases due to the retrospective nature of the analysis and differences in study designs.
Limitations
Different studies had varying selection criteria and assessment time points, which may affect comparisons.
Participant Demographics
Patients included were mostly women with an average age of 52.1 years for RA, 46.8 years for PsA, and 39.8 years for AS.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI: 9.2–11.0 for AS, 7.8–9.4 for PsA, 9.2–11.0 for RA
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website